Flip a Light, Catch a Molecule: New Tools Give Researchers Remote Control Over Cellular Targets
Princeton researchers have engineered molecular tools that attach to their targets when exposed to light — and disengage just as readily when the lights go out. These antibody-like proteins, called OptoBinders, represent an entirely new class of light-switchable tools for controlling cellular activities.
What Are OptoBinders?
OptoBinders are engineered proteins inspired by the structure of antibodies. Their unique feature lies in their ability to snap onto target molecules when illuminated with specific wavelengths of light, and release those targets equally quickly when the light is switched off.
The technology gives researchers precise, remote control over molecular interactions inside living systems — a capability that was difficult or impossible with traditional biochemical tools.
How It Works
The light-responsive behavior stems from a photosensitive domain embedded within each OptoBinder. When photons strike this domain, the protein undergoes a conformational change that either exposes or hides its binding site.
This reversible switching means researchers can initiate or halt molecular interactions with the flick of a light switch — literally. The process is fast, repeatable, and requires no chemical added to the system.
The OptoBinder platform demonstrates that light alone can serve as a precise external trigger for controlling protein-protein interactions in real time.
Potential Applications
The ability to control molecular binding on demand opens doors across multiple fields. Researchers envision using OptoBinders in industrial protein purification processes, where light-triggered release could simplify downstream separation steps. In the realm of sustainable energy, the tools may aid in engineering microorganisms for more efficient biofuel production.
Perhaps most significantly, the technology points toward precision cancer therapies that could be activated on command. By targeting cancer cells with OptoBinders designed to recognize tumor-specific markers, clinicians might one day activate therapeutic agents only where and when they are needed — minimizing damage to healthy tissue.
Based on: OptoBinder Research; Princeton University Department of Chemical and Biological Engineering; Princeton, Date not specified.